From: Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
NCT identifier | Study phase | Treatment | Primary end point |
---|---|---|---|
NCT04582968 | Ib/II | Pyrotinib plus capecitabine combined with brain radiotherapy | Ib: safety and tolerability II: intracranial local tumor control rate |
NCT04767828 | IV | Pyrrolidine maleate and capecitabine combined with brain radiotherapy | Time of intracranial tumor progression |
NCT05042791 | II | Radiation combined with pyrotinib and capecitabine | CNS-ORR |